Skip to content

Study · Animal study (in vivo) · rat · 2006

11 results

Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats.

Thompson EL, Murphy KG, Patterson M, Bewick GA, Stamp GW, Curtis AE, Cooke JH, Jethwa PH, Todd JF, Ghatei MA, Bloom SR

American journal of physiology. Endocrinology and metabolism20 Jun 2006Cited by 103 (Europe PMC)

PMID16787965 (opens in a new tab)DOI10.1152/ajpendo.00040.2006 (opens in a new tab)PepBankPUB-16787965
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, acute subcutaneous kisspeptin‑54 produced the greatest increase in plasma LH at 60 min postinjection among kisspeptin-10, -14 and -54.

    In plain wordsIn rats, kisspeptin‑54 raised luteinizing hormone more than the shorter kisspeptins did one hour after injection.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma LH 60 min after acute dosing
    Study

    ratn: not reported in source

    adult male rats
    Comparator
    Kisspeptin-10 and kisspeptin-14
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Kisspeptin-54 produced the greatest increase in plasma LH and total testosterone at 60 min postinjection and was used in the subsequent continuous administration experiments.
    1 context sentence
    Summary · context
    Initially we compared the effects of acute subcutaneous administration of kisspeptin-10, -14, and -54 on the HPG axis.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, acute subcutaneous kisspeptin‑54 produced the greatest increase in plasma total testosterone at 60 min postinjection among kisspeptin-10, -14 and -54.

    In plain wordsIn rats, kisspeptin‑54 raised testosterone more than the shorter kisspeptins did one hour after injection.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma total testosterone 60 min after acute dosing
    Study

    ratn: not reported in source

    adult male rats
    Comparator
    Kisspeptin-10 and kisspeptin-14
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Kisspeptin-54 produced the greatest increase in plasma LH and total testosterone at 60 min postinjection and was used in the subsequent continuous administration experiments.
    1 context sentence
    Summary · context
    Initially we compared the effects of acute subcutaneous administration of kisspeptin-10, -14, and -54 on the HPG axis.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In adult male rats, continuous subcutaneous kisspeptin‑54 at 50 nmol/day for 13 days decreased testicular weight.

    In plain wordsIn rats, 13 days of continuous kisspeptin‑54 lowered testis weight.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseTesticular weight after 13 days of continuous dosing
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    50 nmol/day · subcutaneous · 13 daysAs given in this study (rat).

    Source sentences

    Summary
    Chronic subcutaneous long-term administration of 50 nmol kisspeptin-54/day for 13 days decreased testicular weight.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In adult male rats given continuous kisspeptin‑54 for 13 days, histology showed degeneration of the seminiferous tubules.

    In plain wordsIn rats, 13 days of continuous kisspeptin‑54 damaged the tubules in the testis where sperm form.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreaseSeminiferous tubule degeneration after 13 days
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    50 nmol/day · subcutaneous · 13 daysAs given in this study (rat).

    Source sentences

    Summary
    Histological examination showed degeneration of the seminiferous tubules
    1 context sentence
    Summary · context
    Chronic subcutaneous long-term administration of 50 nmol kisspeptin-54/day for 13 days decreased testicular weight.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In adult male rats given continuous kisspeptin‑54 for 13 days, circulating inhibin B decreased significantly.

    In plain wordsIn rats, 13 days of continuous kisspeptin‑54 lowered a hormone made by the testes.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseCirculating inhibin B after 13 days
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol/day · subcutaneous · 13 daysAs given in this study (rat).

    Source sentences

    Summary
    associated with a significant decrease in the circulating levels of the testes-derived hormone, inhibin B
    1 context sentence
    Summary · context
    Chronic subcutaneous long-term administration of 50 nmol kisspeptin-54/day for 13 days decreased testicular weight.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In adult male rats given continuous kisspeptin‑54 for 13 days, plasma free testosterone was lower, but the change did not reach statistical significance.

    In plain wordsIn rats, free testosterone was lower after 13 days of continuous kisspeptin‑54, but the difference was not statistically significant.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changePlasma free testosterone after 13 days
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol/day · subcutaneous · 13 daysAs given in this study (rat).

    Source sentences

    Summary
    Plasma free and total testosterone were also lower, although these changes did not reach statistical significance.
    1 context sentence
    Summary · context
    Chronic subcutaneous long-term administration of 50 nmol kisspeptin-54/day for 13 days decreased testicular weight.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In adult male rats given continuous kisspeptin‑54 for 13 days, plasma total testosterone was lower, but the change did not reach statistical significance.

    In plain wordsIn rats, total testosterone was lower after 13 days of continuous kisspeptin‑54, but the difference was not statistically significant.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changePlasma total testosterone after 13 days
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol/day · subcutaneous · 13 daysAs given in this study (rat).

    Source sentences

    Summary
    Plasma free and total testosterone were also lower, although these changes did not reach statistical significance.
    1 context sentence
    Summary · context
    Chronic subcutaneous long-term administration of 50 nmol kisspeptin-54/day for 13 days decreased testicular weight.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, subcutaneous kisspeptin‑54 at 50 nmol for 1 day increased plasma LH.

    In plain wordsIn rats, one day of kisspeptin‑54 raised luteinizing hormone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma LH after 1 day of continuous dosing
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol · subcutaneous · 1 dayAs given in this study (rat).

    Source sentences

    Summary
    Subcutaneous administration of 50 nmol kisspeptin-54 for 1 day increased plasma LH and testosterone.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, subcutaneous kisspeptin‑54 at 50 nmol for 1 day increased plasma testosterone.

    In plain wordsIn rats, one day of kisspeptin‑54 raised testosterone.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma testosterone after 1 day of continuous dosing
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol · subcutaneous · 1 dayAs given in this study (rat).

    Source sentences

    Summary
    Subcutaneous administration of 50 nmol kisspeptin-54 for 1 day increased plasma LH and testosterone.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, the kisspeptin‑54-induced rise in plasma LH was lost after 2 days of continuous administration.

    In plain wordsIn rats, the luteinizing hormone rise caused by kisspeptin‑54 was gone after two days of continuous dosing.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changePlasma LH after 2 days of continuous dosing
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol · subcutaneous · 2 daysAs given in this study (rat).

    Source sentences

    Summary
    Subcutaneous administration of 50 nmol kisspeptin-54 for 1 day increased plasma LH and testosterone. This effect was lost after 2 days of administration, suggesting a downregulation of the HPG axis response to kisspeptin following continuous administration.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In adult male rats, the kisspeptin‑54-induced rise in plasma testosterone was lost after 2 days of continuous administration.

    In plain wordsIn rats, the testosterone rise caused by kisspeptin‑54 was gone after two days of continuous dosing.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changePlasma testosterone after 2 days of continuous dosing
    Study

    ratn: not reported in source

    adult male rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 nmol · subcutaneous · 2 daysAs given in this study (rat).

    Source sentences

    Summary
    Subcutaneous administration of 50 nmol kisspeptin-54 for 1 day increased plasma LH and testosterone. This effect was lost after 2 days of administration, suggesting a downregulation of the HPG axis response to kisspeptin following continuous administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 09:43 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.